High Court Asked To Reject Appeal Of Post-Mensing Ruling

Law360, New York (November 2, 2012, 7:05 PM EDT) -- The plaintiff in a major First Circuit ruling over whether generic-drug companies can be targeted for design defect claims asked the U.S. Supreme Court on Wednesday to block Mutual Pharmaceutical Co.’s appeal, saying the ruling does not conflict with high court precedent.

Karen Bartlett, who won a $23 million design defect judgment against Mutual that the First Circuit upheld in May, argues that Mutual’s petition for a writ of certiorari should be denied on the grounds that the ruling does not conflict with the high court’s...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.